21 CFR 860.250
§ 860.250 Withdrawal of a De Novo request.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 860.250, § 860.250 Withdrawal of a De Novo request, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89016
- Permanent ID
ys:prov:89016@1- SHA-256
54b635d72315bbef9f541d8f9c2b537ca3f663b329f8b2896b5de6ad4a5ebc1b
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) FDA considers a De Novo request to have been withdrawn if:
(1) The requester fails to provide a complete response to a request for additional information pursuant to § 860.240(b)(1) within 180 days after the date FDA issues such request;
(2) The requester fails to provide a complete response to the deficiencies identified by FDA pursuant to § 860.230(c)(2) within 180 days of the date notification was issued by FDA;
(3) The requester does not permit an authorized FDA employee an opportunity to inspect the facilities, pursuant to § 860.240(c), at a reasonable time and in a reasonable manner, and to have access to copy and verify all records pertinent to the De Novo request; or
(4) The requester submits a written notice to FDA that the De Novo request has been withdrawn.
(b) If a De Novo request is withdrawn, the Agency will notify the requester. The notice will include the De Novo request reference number and the date FDA considered the De Novo request withdrawn.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.